Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia

被引：48
|
作者：
Ulhaq, Zulvikar Syambani [1 ]
Soraya, Gita Vita [2 ]
机构：
[1] Maulana Malik Ibrahim Islamic State Univ Malang, Dept Biochem, Fac Med & Hlth Sci, Batu 65151, East Java, Indonesia
[2] Hasanuddin Univ, Dept Biochem, Fac Med, Makassar 90245, South Sulawesi, Indonesia
来源：
MEDICINA CLINICA | 2020年 / 155卷 / 12期
关键词：
OFF-LABEL USE; TOCILIZUMAB; INTERLEUKIN-6;
D O I：
10.1016/j.medcli.2020.07.002
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：548 / 556
页数：9
相关论文
共 50 条
  • [31] The role of IL-6 in ERα plus breast cancer and potential use for Siltuximab, an anti-IL-6 antibody, in ERα plus breast cancer treatment
    Axel, Amy
    Casneuf, Tineke
    King, Peter
    Alvarez, J. D.
    Hall, Brett
    Sasser, Kate
    CANCER RESEARCH, 2013, 73 (08)
  • [32] DNA microarray analysis of SLE related genes that respond to IL-6 blockade with tocilizumab, an anti-IL-6 receptor monoclonal antibody
    Ishikawa, S.
    Aoki, C.
    Yoshio, N.
    Nakahara, H.
    Saito, K.
    Tanaka, Y.
    Kishimoto, T.
    Nishimoto, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 474 - 474
  • [33] COVID-19 PNEUMONIA COMPLICATED BY CMV PNEUMONITIS FOLLOWING TREATMENT WITH AN IL-6 INHIBITOR
    Pandian, Elizabeth
    D'Souza, Gretel
    CHEST, 2021, 160 (04) : 339A - 339A
  • [34] The role of vitamin D receptor and IL-6 in COVID-19
    Azmi, Ali
    Rismani, Maziyar
    Pourmontaseri, Hossein
    Mirzaii, Ebrahim
    Niknia, Sedigheh
    Miladpour, Behnoosh
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2023, 11 (07):
  • [35] Tocilizumab - A humanized anti-IL-6 receptor monoclonal antibody for the treatment of rheumatoid arthritis
    Schlesselman, Lauren S.
    Hussey, Aaron P.
    FORMULARY, 2008, 43 (08) : 272 - 279
  • [36] Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
    Nishimoto, Norihiro
    Terao, Kimio
    Mima, Toru
    Nakahara, Hideko
    Takagi, Nobuhiro
    Kakehi, Takahiro
    BLOOD, 2008, 112 (10) : 3959 - 3964
  • [37] Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?
    Zhang, Yuanyuan
    Zhong, Yanyan
    Pan, Lin
    Dong, Jing
    DRUG DISCOVERIES AND THERAPEUTICS, 2020, 14 (02): : 100 - 102
  • [38] Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report
    Michot, J. -M.
    Albiges, L.
    Chaput, N.
    Saada, V.
    Pommeret, F.
    Griscelli, F.
    Balleyguier, C.
    Besse, B.
    Marabelle, A.
    Netzer, F.
    Merad, M.
    Robert, C.
    Barlesi, F.
    Gachot, B.
    Stoclin, A.
    ANNALS OF ONCOLOGY, 2020, 31 (07) : 961 - 964
  • [39] Clinical significance of IL-6 in severe and critical COVID-19 patients
    Kawamata, Takaya
    Tanino, Yoshinori
    Wang, Xintao
    Nikaido, Takefumi
    Sato, Yuki
    Togawa, Ryuichi
    Watanabe, Natsumi
    Saito, Koshi
    Kazama, Kentaro
    Harigane, Rina
    Yamada, Ryuki
    Tomita, Hikaru
    Rikimaru, Mami
    Morimoto, Julia
    Minemura, Hiroyuki
    Saito, Junpei
    Kanazawa, Kenya
    Shibata, Yoko
    RESPIROLOGY, 2023, 28 : 136 - 136
  • [40] COVID-19: Clean up on IL-6
    Hedrick, Tanner L.
    Murray, Brian P.
    Hagan, Robert S.
    Mock, Jason R.
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2020, 63 (04) : 541 - 543
12345